Warren Buffett, who is known to own “forever stocks,” has famously quipped that if you aren’t willing to own a stock for 10 years, you shouldn’t own it for even 10 minutes.  This idea prompts a good thought exercise: If you could only make a few investments to help you achieve the portfolio growth you’ll need in retirement, which ones would you pick? Get IVV alerts:How to Find Investments Built for Long-Term Success To start, you'll want to analyze the long-term trajectory. Remember that a performance chart ...

Core Viewpoint - Stryker has successfully acquired Inari Medical, enhancing its position in the venous thromboembolism (VTE) market and expanding its interventional endovascular portfolio [1][2]. Company Overview - Stryker is a global leader in medical technologies, offering innovative products and services in MedSurg, Neurotechnology, and Orthopaedics, impacting over 150 million patients annually [5]. Acquisition Details - The acquisition was completed on February 19, 2025, following a cash tender offer of $80.00 per share for Inari's outstanding shares, which resulted in approximately 81.69% of shares being validly tendered [3][4]. - Inari Medical's product portfolio includes the FlowTriever System and ClotTriever System, which are complementary to Stryker's existing Neurovascular business [2][4]. Market Impact - The acquisition positions Stryker to improve patient outcomes in the fast-growing VTE segment, leveraging Inari's innovative solutions for clot removal without thrombolytic drugs [1][2].

Core Viewpoint - Stryker is initiating a cash tender offer to acquire all outstanding shares of Inari Medical for $80.00 per share, following a merger agreement dated January 6, 2025 [1][2]. Group 1: Tender Offer Details - The tender offer will expire on February 18, 2025, unless extended [2]. - The offer is contingent upon a minimum tender of a majority of Inari's shares and the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period [2]. - The transaction is expected to close by the end of Q1 2025 [2]. Group 2: Regulatory Filings - Stryker has filed a tender offer statement with the SEC, detailing the terms of the offer [3]. - Inari's Board of Directors has recommended that its stockholders accept the tender offer [3]. Group 3: Company Profiles - Stryker is a global leader in medical technologies, impacting over 150 million patients annually with innovative products in various medical fields [4]. - Inari Medical focuses on creating innovative solutions for unmet health needs, aiming to establish its treatments as the standard of care for specific medical conditions [5].

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Inari Medical, Inc. (Nasdaq: NARI), relating to the proposed merger with Stryker. Under the terms of the agreement, Stryker will acquire all of the issued and outstanding shares of common stoc ...

Shares of Inari Medical Inc (NASDAQ:NARI) are 21.5% higher in premarket trading, on track to open at nearly $79 amid news that Stryker (SYK) agreed to acquire the medical device maker in an all-cash deal worth roughly $4.9 billion, or $80 per share.NARI yesterday added 30.6%. Factoring today's pre-market performance, the equity is on track to start 2025 with a nearly 50% pop in the first two weeks of trading. Yesterday's close placed Inari Medical stock at its highest level since January 2024, and today's p ...

Inari Medical, Inc. (NARI) shares rallied 30.6% in the last trading session to close at $65. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.6% loss over the past four weeks.Inari Medical recorded a strong price increase after it announced a definitive agreement to be acquired by Stryker Corporation. Per Stryker’s management, Inari Medical’s product portfolio is complementary to Stryker’s Neurovascular busi ...

IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other vascular diseases, announced today that its management team is scheduled to present at the J.P. Morgan Healthcare Conference on Wednesday, January 15 at 8:15 a.m. Pacific Time. Interested parties may access a live webcast and replay of the presentation by visiting the Inari Medical investor relations website. ...

IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced positive results from the prospective PEERLESS Randomized Controlled Trial (RCT) comparing FlowTriever to catheter-directed thrombolytics (CDT). The results were presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine and Co-Global Princ ...

Inari Medical, Inc. (NARI) reported an adjusted loss per share of 13 cents in the third quarter of 2024 against the year-ago reported earnings of 5 cents per share. The Zacks Consensus Estimate for loss per share was pegged at 12 cents. On a GAAP basis, the company recorded a loss per share of 31 cents. Inari Medical registered revenues of $153.4 million, up 21.4% year over year. The figure beat the Zacks Consensus Estimate by 1.7%. Q3 Highlights According to management, Inari Medical's robust sales perform ...